Literature DB >> 12719320

The challenge of an increasingly expensive blood system.

Kumanan Wilson1, Paul C Hébert.   

Abstract

Mesh：

Year:  2003        PMID： 12719320      PMCID： PMC153686     

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  9 in total

Review 1.  The case against universal WBC reduction (and for the practice of evidence-based medicine).

Authors:  L T Goodnough
Journal:  Transfusion       Date:  2000-12       Impact factor: 3.157

2.  A policy analysis of major decisions relating to Creutzfeldt-Jakob disease and the blood supply.

Authors:  K Wilson; P C Hébert; A Laupacis; C Dornan; M Ricketts; N Ahmad; I Graham
Journal:  CMAJ       Date:  2001-07-10       Impact factor: 8.262

Review 3.  Pathogen inactivation of labile blood products.

Authors: 
Journal:  Transfus Med       Date:  2001-06       Impact factor: 2.019

Review 4.  The effectiveness of interventions to reduce physician's levels of inappropriate transfusion: what can be learned from a systematic review of the literature.

Authors:  Kumanan Wilson; Laura MacDougall; Dean Fergusson; Ian Graham; Alan Tinmouth; Paul C Hébert
Journal:  Transfusion       Date:  2002-09       Impact factor: 3.157

Review 5.  Pharmaco-economics of blood transfusion safety: review of the available evidence.

Authors:  M van Hulst; J T M de Wolf; U Staginnus; E J Ruitenberg; M J Postma
Journal:  Vox Sang       Date:  2002-08       Impact factor: 2.144

6.  Red blood cell transfusions in critically ill patients.

Authors:  Paul C Hébert; Dean A Fergusson
Journal:  JAMA       Date:  2002-09-25       Impact factor: 56.272

7.  How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations.

Authors:  A Laupacis; D Feeny; A S Detsky; P X Tugwell
Journal:  CMAJ       Date:  1992-02-15       Impact factor: 8.262

8.  A model of the health and economic impact of posttransfusion hepatitis C: application to cost-effectiveness analysis of further expansion of HCV screening protocols.

Authors:  A Pereira; C Sanz
Journal:  Transfusion       Date:  2000-10       Impact factor: 3.157

Review 9.  US NAT yield: where are we after 2 years?

Authors:  S L Stramer
Journal:  Transfus Med       Date:  2002-08       Impact factor: 2.019
  9 in total
  5 in total

Review 1.  The complexities of multi-level governance in public health.

Authors:  Kumanan Wilson
Journal:  Can J Public Health       Date:  2004 Nov-Dec

2.  The Krever Commission--10 years later.

Authors:  Kumanan Wilson
Journal:  CMAJ       Date:  2007-11-20       Impact factor: 8.262

3.  Recommendations from the Tuscan Transfusion System on the appropriate use of solvent/detergent-inactivated fresh-frozen plasma.

Authors:  Giancarlo Maria Liumbruno; Maria Laura Sodini; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2008-01       Impact factor: 3.443

4.  Operative blood loss, blood transfusion and 30-day mortality in older patients after major noncardiac surgery.

Authors:  Tara M Mastracci; Mohit Bhandari; Raman Mundi; Sandro B Rizoli; Bartolomeu A Nascimento; Martin Schreiber
Journal:  Can J Surg       Date:  2012-12       Impact factor: 2.089

5.  Variant Creutzfeldt-Jakob disease and the Canadian blood system after the tainted blood tragedy.

Authors:  Kumanan Wilson; Ian Graham; Maura Ricketts; Christopher Dornan; Andreas Laupacis; Paul Hebert
Journal:  Soc Sci Med       Date:  2006-10-02       Impact factor: 4.634
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.